Carrier-antibody compositions and methods of making and using the same
AssigneeMayo Foundation for Medical Education and Research
InventorsSvetomir N. Markovic, Wendy K. Nevala
Life of this patent
Estimating the term…
Abstract
Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
Claims10
A lyophilized nanoparticle composition comprising nanoparticles having an outside surface, wherein each of the nanoparticles comprises:
- a) albumin;
- b) between about 100 to about 1000 antibodies having an Fc portion and an antigen-binding portion;
- and
- c) paclitaxel;
- said nanoparticles being lyophilized, and wherein upon reconstitution with an aqueous solution antigen-binding portions of said antibodies are arranged on the outside surface of the nanoparticles and are capable of binding to VEGF in vivo wherein said antibody is a humanized antibody, a chimeric antibody, a non-human antibody, a monoclonal antibody, a CDR-grafted antibody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding fragment thereof, or a bifunctional hybrid antibody, and wherein the average size of the nanoparticles is between 130 nm and 800 nm.
A lyophilized composition comprising nanoparticle complexes having an outside surface, wherein each of the nanoparticle complexes comprises:
- a) albumin;
- b) between about 100 to about 1000 antibodies, each having a Fc portion and an antigen-binding portion, wherein antigen-binding portions of the antibodies are arranged on the outside surface of the complex;
- and
- c) paclitaxel;
- said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the nanoparticle complexes remain capable of binding to VEGF in vivo, wherein said antibody is a humanized antibody, a chimeric antibody, a non-human antibody, a monoclonal antibody, a CDR-grafted antibody, a multispecific antibody, a dual specific antibody, an anti-idiotypic antibody, a bispecific antibody, a functionally active epitope-binding fragment thereof, or a bifunctional hybrid antibody, and further wherein said complexes have an average size of from about 130 nm to about 800 nm;
- wherein the lyophilized composition does not contain a bulking agent.
Dependencies are inferred from the claim text.